IRIS
MARRONE, Aldo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.260
EU - Europa 4.083
AS - Asia 677
AF - Africa 9
SA - Sud America 8
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 1
Totale 9.044
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.235
IE - Irlanda 1.376
UA - Ucraina 687
GB - Regno Unito 558
IT - Italia 483
CN - Cina 462
DE - Germania 326
SE - Svezia 237
FI - Finlandia 172
TR - Turchia 170
GR - Grecia 127
FR - Francia 60
BE - Belgio 22
CA - Canada 21
SG - Singapore 11
IN - India 10
NL - Olanda 10
CZ - Repubblica Ceca 7
IR - Iran 7
EU - Europa 6
ID - Indonesia 6
EG - Egitto 5
RO - Romania 5
JP - Giappone 4
RU - Federazione Russa 4
AR - Argentina 3
CH - Svizzera 3
HR - Croazia 3
MX - Messico 3
CL - Cile 2
PE - Perù 2
TW - Taiwan 2
UG - Uganda 2
VN - Vietnam 2
AM - Armenia 1
BD - Bangladesh 1
BR - Brasile 1
BW - Botswana 1
HU - Ungheria 1
JM - Giamaica 1
LI - Liechtenstein 1
MA - Marocco 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
Totale 9.044
Salva come PNG Salva come JPEG
Città #
Dublin 1.370
Jacksonville 1.045
Chandler 730
New York 256
Princeton 210
Roxbury 158
Woodbridge 139
Ann Arbor 126
Boardman 123
Cambridge 116
Bremen 112
Wilmington 104
Medford 100
Caserta 63
Jinan 57
Beijing 56
San Mateo 53
Shenyang 52
Nanjing 50
Ashburn 48
Des Moines 44
Mountain View 41
Düsseldorf 33
Zhengzhou 29
Naples 28
Nanchang 25
Brussels 22
Napoli 22
Houston 21
Norwalk 19
Washington 19
Changsha 17
Haikou 17
Guangzhou 15
Hangzhou 15
Hebei 15
Los Angeles 14
Ningbo 14
Auburn Hills 13
Lanzhou 13
Tianjin 12
Helsinki 11
Taiyuan 11
Taizhou 11
Kunming 10
Ottawa 10
Seattle 10
Shanghai 9
Singapore 9
Dearborn 8
Jiaxing 8
Marano Di Napoli 8
Amsterdam 7
Rome 7
Milan 6
Marigliano 5
Munich 5
Portici 5
Redwood City 5
Rossano 5
Zanjan 5
Andover 4
Atlanta 4
Changchun 4
Hefei 4
Padova 4
Sacramento 4
Toronto 4
Venice 4
Avellino 3
Elora 3
Frattamaggiore 3
London 3
Palermo 3
Paris 3
Perugia 3
San Francisco 3
San Giuseppe Vesuviano 3
Tokyo 3
Zurich 3
Athens 2
Bari 2
Barlassina 2
Bergamo 2
Bologna 2
Bonea 2
Brdo 2
Bucharest 2
Casteldaccia 2
Cava de' Tirreni 2
Chennai 2
Elice 2
Fairfield 2
Florence 2
Fuzhou 2
Genoa 2
Gioi 2
Groningen 2
Hyderabad 2
Lappeenranta 2
Totale 5.676
Salva come PNG Salva come JPEG
Nome #
Cannabinoid receptor 2-63 QQ varianti s associated with severe necroinflammation in chronic epatiti C 106
Mechanisms and clinical behavior of hepatocellular carcinoma in HBV and HCV infection and alcoholic and non-alcoholic fatty liver disease 100
Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment. 89
Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration 89
Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms 81
Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C 77
Association Between a Polymorphism in Cannabinoid Receptor 2 and Severe Necroinflammation in Patients With Chronic Hepatitis C. 75
null 71
Anti-envelope 1 and 2 immune response in chronic hepatitis C patients: Effects of hepatitis B virus co-infection and interferon treatment 71
IMPACT OF TYPE II DIABETES ON HCC APPEARANCE IN PATIENTS TREATED WITH DIRECT ACTING ANTIVIRALS 69
Effect of prednisone priming followed by alpha-interferon in treatment of children with chronic hepatitis B: an interim analysis of a controlled trial 68
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 68
Analisi della regione del core promoter del virus dell’epatite B (HBV) in pazienti guariti da una malattia oncoematologica con infezione cronica da HBV o da HBV-HCV tre anni dopo sieroconversione ad anti-HBe. 67
The impact of the CB2-63 polymorphism on the histological presentation of chronic hepatitis B. 66
Espressione dell'infezione da citomegalovirus (CMV) in pazienti cardiotrapiantati 65
Chronic HCV infection and neurological and psychiatric disorders: an overview. 63
PNPLA3 l148M variant as a risk factor for carotid atherosclerosis in chronic epatiti C 63
Three-phase sequential combined treatment with lamivudine and interferon in young patients with chronic hepatitis B 61
Pleurite da Listeria monocytogenes in un paziente con cirrosi epatica: osservazione di un caso clinico 61
Le complicanze infettive in pazienti sottoposti a trapianto di cuore: dati del centro napoletano. 60
Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. 60
Esperienza con l'interferone linfoblastoide nelle epatiti croniche virali 59
Long term effect of interferon (IFN) treatment of chronic hepatitis B (CHB) in pediatric patients cured of oncologic diseases 59
Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection 58
Activity of aminoglycosides against phagocytosed bacteria 58
Favourable effect of alpha-interferon treatment in HBeAb/HBV-DNA positive chronic hepatitis B. 58
Leukocyte interferon-alpha and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon 57
Cannabinoid Receptor 2 (CB2) Q63 variant in chronic hepatitis C: an association with a more severe hepatocellular necrosis. 57
Ruolo patogenetico dell'adiponectina nella steatosi associata ad epatite C 57
Patatin-Like Phospholipase Domain-Containing 3 I148M Variant Is Associated with Liver Steatosis and Fat Distribution in Chronic Hepatitis B 57
Interferon-induced anti-HBE seroconversion correlates with a Th1 cytokine shift following emergence of core promoter mutations in chronic hepatitis B 56
Prolonged treatment of children with chronic hepatitis B with recombinant alpha 2a-interferon: a controlled, randomized study 56
Advances in the Diagnosis and Monitoring of Hepatitis C Virus Infection 56
Ricerca del sangue occulto nelle feci con Hemoquant: prevenzione e diagnostica. 56
Le infezioni respiratorie da Branhamella catarrhalis in pazienti sottoposti a trapianto di cuore. 56
Treatment of chronic hepatitis B in children with prednisone followed by alpha-interferon: a controlled randomized study 55
Analisi della regione del core promoter del virus dell’epatite B (HBV) in pazienti guariti da una malattia oncoematologica con infezione cronica da HBV o da HBV-HCV tre anni dopo sieroconversione ad anti-HBe 55
Cannabinoid receptor 2 (CB2) Q63 variant is associated with a severe histological activity index in patients with chronic hepatitis C 55
Different serological, molecular and cytokine profiles characterize active and inactive disease in patients with chronic hepatitis B virus (HBV) infection 55
Eighteen months lamivudine prophylaxis of occult HBV infection (OBI) reactivation and standard therapy of overt chronic infection in oncohematologic immunosuppressed patients: an interim analysis 55
Complicanze infettive in pazienti sottoposti a trapianto di cuore. 55
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 54
Effects of long-term alfa interferon treatment in 344 patients with chronic hepatitis C: retrospective analysis of dosage and type of interferon used 54
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. 54
Absence of hepatitis C viral infection among patients with primary Sjogren's syndrome 54
Favourable effect of alpha-interferon treatment in HBeAb/HBV-DNA positive chronic hepatitis B 54
CB2-63 polymorphism and immune-mediated diseases associated with HCV chronic infection. 54
Tenofovir disoproxil fumarate monotherapy maintains HBV suppression achieved by a "de novo" combination of lamivudine-adefovir: a pilot study 54
Core promoter mutations 3 years after anti-hepatitis B e seroconversion in patients with chronic hepatitis B or hepatitis B and C infection and cancer remission 53
Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. 53
EFFICACIA DEL TRATTAMENTO CON INTERFERONE RICOMBINANTE E LINFOBLASTOIDE IN PAZIENTI CON EPATITE CRONICA DA HCV 53
Hepatitis C virus infection in Italy: a multicentric sero-epidemiological study. (A report from the HCV study group of the Italian Association for the study of the liver) 52
Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C 52
Interferon plus lamivudine treatment in young patients with chronic active B and C hepatitis 52
Severe diarrhea occurring during alpha-interferon treatment for chronic hepatitis C is associated with serologic markers of celiac disease 52
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine 51
Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression. 51
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta 51
Chronic hepatitis B infection in pediatric patients cured of oncologic diseases: natural history and effect of interferon treatment 51
Correlation of serum HBeAg levels and double A1762T/G1764A HBV core promoter mutation with response to interferon in patients with chronic hepatitis B 51
Epidemiology of HCV and HBV in a High Endemic Area of Southern Italy: Opportunities from the COVID-19 Pandemic—Standardized National Screening or One Tailored to Local Epidemiology? 50
Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis 50
Le infezioni delle basse vie urinarie: eziologia e suscettibilità agli antibiotici. Nostra esperienza negli ultimi 4 anni. 50
Ruolo patogenetico dell’adiponectina nella steatosi associata ad epatite C 50
Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. 50
Immunocompromised patients with HBsAg a determinant mutants: comparison of HBsAg diagnostic assays 49
Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients 49
Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia 49
HCV-related steatosis and risk of atherosclerosis 49
La epatite cronica da HCV con steatosi si associa ad elevato rischio aterosclerotico. 49
Efficacia del trattamento con interferone ricombinante e linfoblastoide in pazienti con epatite cronica da HCV. 49
Hepatitis B virus DNA quantitation and detection of core promoter, precore and polymerase mutations in chronic hepatitis B: evaluation and clinical usefulness of three new commercial assays 48
SEQUENTIAL ANALYSIS OF HEPATITIS B VIRUS CORE PROMOTER AND PRECORE REGIONS IN CANCER SURVIVOR PATIENTS WITH CHRONIC HEPATITIS B BEFORE, DURING AND AFTER INTERFERON TREATMENT 48
Tm6sf2 e167k variant is associated with severe steatosis in chronic hepatitis c, regardless of pnapl3 polymorphism 48
Genetic heterogeneity of hepatitis C virus. The clinical significance of genotypes and quasispecies behavior 48
Baseline HBV-DNA level is an important predictor of response to interferon in children with chronic hepatitis B 48
Le infezioni respiratorie da Branhamella catarrhalis in pazienti sottoposti a trapianto di cuore 48
Infezioni respiratorie da Branhamella Catarralis in pazienti sottoposti a trapianto di cuore 48
Efficacia e tollerabilità dell'alfa interferone (IFN) nell'epatite cronica post-trasfusionale (PTCH) da HCV: dati preliminari di soggetti precedentemente sottoposti a cardiochirurgia. 48
Suscettibilità antibiotica di enterococchi recentemente isolati. 48
ESPERIENZA CON L'INTERFERONE LINFOBLASTOIDE NELLE EPATITI CRONICHE VIRALI 48
Chronic HCV infection is a risk factor of ischemic stroke 48
Risk factors for carotid atherosclerosis in chronic hepatitis C: no role of the APOC3 variant 48
Aspetti diagnostici di mutanti della regione HBsAg in pazienti immunocompromessi con riattivazione dell’infezione da virus dell’epatite B (HBV). 47
Clearance of HBsAg and HBV-DNA after lamivudine (LAM) or entecavir (ET) rescue therapy in oncohaematological patients with hepatitis B virus (HBV) reactivation: complete recovery of four cases 47
The TM6SFZ 8167K variant is an independent predictor of severe liver steatosis in chronic hepatitis C 47
The significance of hepatitis G virus in serum of patients with sporadic fulminant and subfulminant hepatitis of unknown etiology 46
Studio dellla suscettibilità antibiotica di stafilococchi responsabili di infezioni nosocomiali 46
Studio prospettico controllato del trattamento prednisone interferone in pazienti pediatrici con epatite cronica da HBV 46
Efficacia e sicurezza dell’entecavir nel controllo dell’infezione da HBV nel paziente oncoematologico 46
Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy 46
Low HBeAg serum levels correlate with the presence of the double A1762T/G1764A core promoter mutation and a positive response to interferon in patients with chronic hepatitis B virus infection 45
Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection 45
Treatment of chronic hepatitis B in children with prednisone followed by alfa-interferon: a controlled randomized study 45
The epidemiology of hepatitis delta infection in Italy 45
NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. 45
Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment. Predictive Factors and Role of Epigenetics 45
COVID-19 and arrhythmia: The factors associated and the role of myocardial electrical impulse propagation. An observational study based on cardiac telemetric monitoring 43
Le infezioni delle basse vie urinarie: eziologia e suscettibilità agli antibiotici.Nostra esperienza negli ultimi 4 anni. 43
Chronic hepatitis C does not impair the physiologic increase of erythropoietin production in response to the ribavirin-induced anemia 43
Totale 5.550
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.525
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.525
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201923 0 0 0 0 0 0 0 0 0 0 12 11
2019/20201.086 219 190 10 7 193 34 229 39 59 32 62 12
2020/20211.682 120 15 173 95 435 16 205 159 8 214 175 67
2021/20221.285 59 3 8 15 435 14 11 35 64 124 103 414
2022/20232.729 235 47 40 222 332 226 4 177 1.295 27 64 60
2023/20241.001 96 33 61 97 373 262 17 35 4 14 9 0
Totale 9.424